As announced previously, Mylan exercised its option to acquire these businesses as part of the original, October 2007 agreement in which Mylan acquired Merck KGaA’s generics business in Western Europe, Asia-Pacific, Africa and North America.
Mylan has said that the acquisition does not require any additional consideration from Mylan to Merck KGaA.
Robert Coury, vice chairman and CEO of Mylan, said: “Our acquisition of the Central and Eastern Europe (CEE) businesses gives us access to an additional area with significant growth opportunities for generics. It reflects our global strategy to leverage existing platforms, rather than create start-up organizations.”